Novacyt: Results of the capital increase

Novacyt, a specialist in clinical diagnostics, has announced the results of its capital increase with maintenance of shareholders' preferential subscription rights. This transaction follows the acquisition of Southern Cross Diagnostics, opening new markets in Australia and Asia-Pacific. Novacyt raised €784,736 through the issuance of 1,961,840 new shares, including 1,041,348 subscribed by Ardenna PTY Ltd, the former owner of SCD, for €416,539.20.

Overall demand exceeded the number of shares initially offered, reaching 125.2% with 2,456,286 shares requested. The company's share capital will now amount to €4,839,205.87, divided into 72,588,088 shares. The funds raised will strengthen shareholders' equity.

The new shares will be admitted to trading on Euronext Growth Paris and AIM. The transaction did not require an AMF prospectus. The lock-up commitments include a 12-month holding period for the shares by Ardenna PTY Ltd.